Related references
Note: Only part of the references are listed.Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A Real-World Data Analysis
Alberto Bongiovanni et al.
NEUROENDOCRINOLOGY (2021)
Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms
Sho Hasegawa et al.
INTERNAL MEDICINE (2021)
Present and future of immunotherapy in Neuroendocrine Tumors
Manuela Albertelli et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2021)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2020)
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Johannes Hofland et al.
ENDOCRINE REVIEWS (2020)
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
Samuel Adant et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Somatostatin Analogs in Clinical Practice: A Review
Mariana Gomes-Porras et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
Arvind Dasari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
J. Xu et al.
ANNALS OF ONCOLOGY (2020)
Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)
Ryo Shimoyama et al.
PANCREATOLOGY (2020)
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
Si-Yang Liu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Combination Strategies to Improve Targeted Radionuclide Therapy
Tiffany G. Chan et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
Mauro Cives et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors
Matthias Beyens et al.
ENDOCRINE-RELATED CANCER (2019)
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
Juan W. Valle et al.
FUTURE ONCOLOGY (2019)
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications
Mauro Cives et al.
NEUROENDOCRINOLOGY (2019)
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
Anna Yordanova et al.
CLINICAL NUCLEAR MEDICINE (2019)
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
Anna Kathrin Stueven et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
Sebastian Krug et al.
PLOS ONE (2019)
LBA76Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
J Xu et al.
ANNALS OF ONCOLOGY (2019)
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
Javier Pozas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Satya Das et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs)
Lei Cai et al.
CLINICAL CANCER RESEARCH (2019)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lingaku Lee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Periostin Limits Tumor Response to VEGFA Inhibition
Ioanna Keklikoglou et al.
CELL REPORTS (2018)
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Chester E. Chamberlain et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Gastroenteropancreatic Neuroendocrine Tumors
Mauro Cives et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms A meta-analysis
Yaoheng Lu et al.
MEDICINE (2018)
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years
Paul E. Sackstein et al.
SEMINARS IN ONCOLOGY (2018)
Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
Anna Angelousi et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
Jian Ming Xu et al.
ONCOTARGET (2017)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Bryan Oronsky et al.
NEOPLASIA (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors
Sebastian Krug et al.
DIGESTION (2017)
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Tetsuhide Ito et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
A. J. Zurita et al.
BRITISH JOURNAL OF CANCER (2015)
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Yujie Zhao et al.
ONCOLOGIST (2015)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial
Emmanuel Mitry et al.
EUROPEAN JOURNAL OF CANCER (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Illuminating somatostatin analog action at neuroendocrine tumor receptors
Jean Claude Reubi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development
S. M. Pyonteck et al.
ONCOGENE (2012)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Share Paper
